First patient enrolled in TearCare trial for dry eye

Sight Sciences has enrolled the first subject in the OLYMPIA pivotal trial of TearCare for dry eye disease, the company announced in a press release.

TearCare is a wearable, personalized, open-eye technology that delivers regulated, localized heat to the eyelids. The prospective, multicenter, randomized OLYMPIA study will evaluate TearCare compared with LipiFlow (Johnson & Johnson Vision) in 138 subjects with meibomian gland dysfunction, the release said.

“Our team has worked diligently over the past 6 years to design a system that is intended to set a new bar for dry eye therapy. This trial brings us one step closer to our vision of delivering a better dry eye treatment experience for both patients and eye care professionals,” Paul Badawi, co-founder and CEO of Sight Sciences, said in the release.

Sight Sciences has enrolled the first subject in the OLYMPIA pivotal trial of TearCare for dry eye disease, the company announced in a press release.

TearCare is a wearable, personalized, open-eye technology that delivers regulated, localized heat to the eyelids. The prospective, multicenter, randomized OLYMPIA study will evaluate TearCare compared with LipiFlow (Johnson & Johnson Vision) in 138 subjects with meibomian gland dysfunction, the release said.

“Our team has worked diligently over the past 6 years to design a system that is intended to set a new bar for dry eye therapy. This trial brings us one step closer to our vision of delivering a better dry eye treatment experience for both patients and eye care professionals,” Paul Badawi, co-founder and CEO of Sight Sciences, said in the release.